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Abstract. 
Original metallo phosphorus dendrimers (generation 3, 48 terminal groups) have been prepared via 
the complexation of phosphorus dendrimers bearing imino-pyridino end groups with Au(III) or both 
with Au(III) and Cu(II) The complexation of the dendrimer with Au(III), leading to 1G3-[Au48] [AuCl4]48, 
strongly increased the anti-proliferative activities against both KB and HL-60 tumoral cell lines, 
showing IC50’s in the low nanomolar range. It can be noticed also that this gold conjugated 
phosphorus dendrimer displayed low activity on the quiescent cell line EPC versus its potent 
antiproliferative activity against actively dividing cells. In order to evaluate the potential synergistic 
effect between Au(III) and Cu(II) and the influence of the number of Au(III) moieties on the surface of 
dendrimer against the proliferative activities, nine other original dendrimers with several surface 
modifications have been prepared. Whatever the number of Au(III) moieties introduced on the 
surface of dendrimers, all the dendrimers prepared displayed similar potency (nanomolar range) to 
1G3-[Au48] [AuCl4]48 against KB and HL60. In marked contrast synergistic effect on the antimicrobial 
activity of some of these phosphorus dendrimers are observed when both Au (III) and Cu(II) are 
present on the dendritic structure.  
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Introduction 
Cancers remains one of the major leading cause of mortality in both developed and developing 
countries with over 10 million new cases every year.1 Oncology is one of the fastest-growing 
therapeutic areas in the pharmaceutical industry.2 Intensive and sustained research efforts in 
oncology during more than fifty years have led to the development of various partially curative 
strategies and the hope is now based on the combined efforts of various branches of science 
including oncology, biology, chemistry, physics and material science and engineering. New types of 
functional materials have been developed and are currently used in several fields of pharmaceutics 
and curative medicine including the field of oncology. Forty-five new drugs were approved in 2015, 
and the Food Drug Administration (FDA) approved 14 (~31%) cancer drugs in 2015.3 The oncology 
field has accounted for over 30% of the approvals for 3 of the past 4 years.  
Nanotechnology has immensely progressed in the last 20 years to supply important advances in 
several different domains such as early diagnosis and prevention, bioimaging, therapies, and drug 
and gene delivery systems.4,5,6 Within the nanotechnology universe, the remarkable unique and 
tunable properties of dendrimers have made them promising tools for diverse biomedical 
applications such as drug delivery, gene therapy and diagnostic methods.7 Dendrimers are highly 
branched macromolecules with nanometer-scale dimensions. Three different components define 
dendrimers:  a central core, an interior dendritic structure (named branches), and an external surface 
with the possibility to graft multiple functional type groups. Numerous varied combination of these 
three components yield nanomaterials of different sizes, shapes internal cores, and are ideal 
candidates for instance for biological applications. A large number of small molecules or polymer 
metal complexes as therapeutic agents in the oncology domain were reported. Several informative 
reviews highlighted the use of metallodrugs in the oncology domain (unexhaustive list).8,9,10,11,12,13 
To date, very few examples have described the preparation of dendrimer conjugated-metallodrugs. 
In early studies, Malik et al. conjugated G3.5 PAMAM-CO2H dendrimers with cisplatin giving PAMAM-
platinate complexes (mono-, bi- and crosslinked-dentates).14,15,16 In in vivo studies, dendrimer 
conjugated-Pt displayed equi-activity with cisplatin by i.p. route against intra-peritoneally grafted 
L1210 leukaemia tumour model in mice with a T/C > 191% versus 171%, which is the maximal 
cisplatin tolerated dose (MTD) of cisplatin. At the highest dose of 15 mg/kg i.p., dendrimer 
conjugated-Pt, showed very good activity against B16F10 melanoma model (T/C = 129%), whereas 
cisplatin, at its MTD dose, did not. 
Beside PAMAM dendrimers, the first generation of the poly(propyleneimine)dendrimer (DAB(PA-Pt-
Cl)4) substituted with four trans-diaminechloroplatinum moieties has been described.
17 This four-
armed complex can be expected to form crosslinks with DNA that are different from adducts formed 
with cisplatin, and consequently, potentially overcome cisplatin resistance in cancer cells. This 
complex showed low cytotoxicity against the L1210/0 and L1210/2 mouse leukaemia cell lines and 
against seven human tumor cell lines (MCF7, EVSA-T, WIDR, IGROV, M19, A498 and H226 cells). 
An anionic biocompatible G2-citric acid-based dendrimer-Pt showed potent in vitro cytotoxic 
activities not only against Pt sensitive human fibrosarcoma (HT1080) and carcinoma (CT26) tumour 
cell lines (up to 8-fold versus cisplatin alone), but also against Pt resistant cell lines such as human 
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ovarian carcinoma (SK-OV-3). An approximatively 2-fold increase in comparison with cisplatin alone 
was observed.18 
Several Pt(II)-dendrimer conjugates have been also prepared, and displayed weak cytotoxicity against 
human breast adenocarcinoma cell line (MCF-7) in contrast to complexes A(PtCl2)2 and C(PtCl2)2 
showing good potency against MCF-7.19 
In another example, Jang et al. have also reported interesting conjugates. Thus, cis-
dichlorodiamineplatinum(II), a derivative of cisplatin, was loaded onto phthalocyanine dendrimer, 
which led to polymer-metal-complex micelles that are useful for sustained drug releasing and 
photodynamic therapy. To the best of our knowledge, no antitumor activities have been reported for 
these products.20 
Following Chu and collaborators, several works were carried out on the synthesis and cytotoxicity of 
transition metal complexes with Schiff base ligands. The authors have reported the synthesis of Pt(II), 
Pd(II), Cu(II), and Hg(II) complexes with N-[2-(pyridine-2-ylmethylidene)amino)ethyl]acetamide 
showing moderate to low activities against human leukaemia (MOLT-4) and breast cancer (MCF-7), 
and no activity against non-cancerous Chang Liver cell lines.21,22 
More recently the importance of ruthenium metallodendrimers was nicely pointed out using either 
arene ruthenium carbosilane dendrimers,23 arene ruthenium metallacages pyrenyldendrimers,24 and 
ruthenium-PTA phosphorus dendrimers.25 Another example was reported by Sadler’s group 
consisting of the synthesis of different organometallic osmium arene complexes with substituted 
phenylazopyridines as chelating ligands. The most potent complexes were cytotoxic at nanomolar 
concentrations toward ovarian, lung, breast colon, prostate and bladder human cancer cells, with an 
order of magnitude higher than cisplatin alone.26 
Recently, within our goal to develop new anticancer agents in the dendrimer space27, we have shown 
that the multivalent Cu-conjugated analogue 1G3-Cu48 displayed a high efficiency against several 
human cancer cell lines (IC50≈ 0.5-0.6µM), and thus might constitute a new anti-tumour candidate for 
chemotherapy (Figure 1).28 Its non-complexed analogue 1G3 was found to be less active against the 
same tumor cell lines (IC50≈1.2-1.5µM). 
Basically, we have shown that 1G3 moderately activated caspase-3 activity whereas 1G3-Cu48 actively 
promoted the translocation of Bax to the mitochondria, the release of AIF to the nucleus and a 
severe fragmentation of DNA, hallmark of apoptosis.  29 
The promising results of 1G3 and 1G3-Cu48 prompt us to investigate the effect of the replacement of 
all the 48 Cu(II) groups of 1G3-Cu48 by Au(III) named 1G3-[Au48] [AuCl4]48 (Figure 1) on the anti-
proliferative and antimicrobial activities of this original metallodendrimer.  
Results and discussion 
Anticancer activities 
 
The first goal of this study is to analyse the influence of metal-type on the antiproliferative profile. 
Two different tumour cell lines representative markers for anticancer activity have been chosen: a 
solid tumour (KB, epidermal carcinoma) and the leukaemia HL60 (promyelocytic) cells. In addition, 
two non-cancer cell lines, namely, MCR5 (proliferative human lung fibroblasts) and the quiescent EPC 
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(endothelial progenitor cells, Cyprinus carpio) have also been selected to figure a “safety ratio” by 
the evaluation of “normal” dividing and non-dividing cells.  
 
Figure 1. Chemical structure of 1G3, 1G3-Cu48 and 1G3-[Au48] [AuCl4]48 dendrimers X = nothing for 
1G3; X = CuCl2 for 1G3-Cu48; X = [AuCl2] [AuCl4] for 1G3-[Au48] [AuCl4]48 
 
We first evaluated the antiproliferative potency of the mononuclear compound 1 which represents 
the terminal function of 1G3-[Au48] [AuCl4]48 (Figure 2), as well as the potential synergistic effects 
between Au(III) and Cu(II) and the influence of the number of Au(III) on the dendrimer surface 
against the proliferative - and also - antimicrobial activities by preparing new dendrimers containing 
Au(III) moieties and variable numbers of N-(pyridin-2-ylmethylene) ethanamine (named NN) groups, 
Cu(II)Cl2 named Cux where x is the number of Cu(II) units complexed to the NN ligands and PEG 
chains. 
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As shown in Table 1, the replacement of Cu(II) by Au(III) increased considerably the anti-proliferative 
activity: 1G3-[Au48] [AuCl4]48 (prepared from the reaction of 1G3 with 96 equivalents of AuCl3,see 
supplementary information) showed IC50s of 7.5 nM and 3.3 nM against KB and HL60, respectively, 
while 1G3-Cu48 displayed IC50’s of 470 nM and 580 nM against KB and HL60, respectively. No or very 
weak effect has been observed against the viability of quiescent cell line EPC with both 1G3-Cu48 and 
1G3-[Au48] [AuCl4]48 (IC50s ≥ 1µM), whereas IC50s of 1G3-Cu48 and 1G3-[Au48] [AuCl4]48 are of ~800nM 
and ~12nM against the proliferating non-tumoral MRC5 human cell line. Such values have to be 
compared with the known antitumoral activity of cisplatin showing IC50s of 6.3 and 11.6 µM against 
KB and HL60, respectively). 
Similar safety ratios can be calculated in actively dividing cells (IC50 MRC5/IC50 KB or HL60) for both 
1G3-Cu48 and 1G3-[Au48] [AuCl4]48 whereas the safety ratio raised considerably in quiescent cells 
compared to actively dividing cells (IC50 EPC/IC50 KB or HL60) with 1G3-[Au48] [AuCl4]48 but remained 
unchanged with 1G3-Cu48. Thus, unlike 1G3-Cu48, 1G3-[Au48] [AuCl4]48 might preferentially target 
cells in active division. 
IC50 (nM) KB HL60 EPC MRC5 Safety ratio 
1G3-Cu48 470±20 580±70 1380±20 800±180 2.9-2.4* 1.7-1.4** 
1G3-[Au48] 
[AuCl4]48 
7.5±7.5 3.3±0.6 >1000 12±5 133-300* 1.6-3.6** 
* IC50 (EPC)/IC50 (KB or HL60) ** IC50 (MRC5)/IC50 (KB or HL60) 
Table 1. Anti-proliferative activities of 1G3-Cu48 and 1G3-[Au48] [AuCl4]48  
To delineate the respective role of the plain dendrimer 1G3 and AuCl3, the mixture of the non-
complexed 1G3 plus AuCl3 and of the stable complex 1G3-[Au48] [AuCl4]48 we measured their growth 
inhibition potency. As expected from previous data obtained with CuCl2,
28 AuCl3 retained a low 
intrinsic activity (% inhibition: 55±6% cell death at 33 nM) and the association of AuCl3 with the plain 
1G3 (% inhibition: 45±5% cell death at 33 nM) did not potentiate the intrinsic antiproliferative effect 
of 1G3 (% inhibition: 44±6% cell death at 33 nM) compared to that of the complexed 1G3-[Au48] 
[AuCl4]48 (% inhibition: 89±5% cell death at 33 nM). 
Therefore 1G3-[Au48] [AuCl4]48 represents a very interesting new nanodrug against solid tumour and 
leukaemia cell lines. The exact chemical structure of 1G3-[Au48] [AuCl4]48 has been determined from 
the X-ray determination of the Au(III)-monomer complex 1 (Figure 2). Two different Au(III) types 
were observed: one cationic [AuCl2]
+ moiety complexed with N-(pyridin-2-ylmethylene) ethanamine 
moiety and one anionic Au moiety under Au(III)Cl4
- counterion form. The mononuclear complex 1 
was also tested against KB, HL60 and EPC cell lines to evaluate the role of the corresponding 
mononuclear entity on the anti-proliferative activity and the safety ratio. 1 displayed IC50’s of ~150 
nM and 65-75 nM against KB and HL60, respectively, and >10 µM against EPC.  
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Figure 2: Chemical structure and X-ray structure of the Au(III)-monomer complex 1  
The next step was the analysis of the influence of the number and the nature of metal moieties 
distribution on the surface of the 1G3 dendrimer (Figure 3). We focused our attention on the 
preparation of nine original dendrimers based on 1G3 chemical structure with several surface 
modifications such as keeping free some of the N-(pyridin-2-ylmethylene) ethanamine (named NN) 
ligands, or complexing them partially with Cu(II)Cl2, and Au(III)Cl3 or introducing some PEG chains (n = 
11) to evaluate the potential synergistic effect between Au(III) and Cu(II) and the influence of the 
number of Au(III) moieties against the proliferative activities. PEG chains have been selected to 
increase both the water solubility of corresponding dendrimers, and also potentially to increase their 
biocompatibility e.g. improvement of the circulating time in the blood The following dendrimers have 
been prepared: 44 N-(pyridin-2-ylmethylene) ethanamine (NN) groups and 4 PEG chains termed 1G3-
[NN44-PEG4], 40 N-(pyridin-2-ylmethylene) ethanamine (NN) groups and 8 PEG chains termed 1G3-
[NN40-PEG8], 30 N-(pyridin-2-ylmethylene) ethanamine (NN) groups and PEG chains termed 1G3-
[NN30-PEG18], 30 Au(III), 15 N-(pyridin-2-ylmethylene) ethanamine (NN) groups, and 18 PEG named 
1G3-[Au15-NN15-PEG18][AuCl4]15, 40 Au(III), 20 N-(pyridin-2-ylmethylene) ethanamine moieties and 8 
PEG chains named 1G3-[Au20-NN20-PEG8] [AuCl4]20, 44Au(III), 22 N-(pyridin-2-ylmethylene) 
ethanamine moieties and 4PEG 1G3-[Au22-NN22-PEG4] [AuCl4]22, 80Au[III),8PEG named 1G3-[Au40-
PEG8] [AuCl4]40, 40 Au(III) 20 Cu(II) and 8 PEG named 1G3-[Au20-Cu20-PEG8] [AuCl4]20 which represent 
also first-in-class dual Cu(II)-Au(III) dendrimers; 20 Au(III), 20 Cu(II),10 N-N and 8 PEG named 1G3-
[Au10-Cu20-NN10-PEG8] [AuCl4]10 (Figure 3). All of these dendrimers incorporate therefore stochastic 
number of functional group types on their respective surface.  
The Table 2 highlights the anti-proliferative activities of the new dendrimers against KB, HL60 tumour 
cell lines and the EPC quiescent cell line. Figure 4 shows the antiproliferative activities (against KB 
and HL60 cells) of the prepared dendrimers, and the Figure 5 summarizes the antiproliferative 
activities in relation with the number of Au(III) moieties on the surface of 1G3 phosphorus 
dendrimers versus Cu(II), PEG and N-N groups on the surface. 
Interestingly, we noted that 1G3-[Au20-NN20-PEG8][AuCl4]20, 1G3-[Au10-Cu20-NN10-PEG8] [AuCl4]10, 
1G3-[Au20-Cu20-PEG8] [AuCl4]20, 1G3-[Au22-NN22-PEG4][AuCl4]22 and 1G3-[Au40-PEG8][AuCl4]40 
displayed similar potency to 1G3-[Au48] [AuCl4]48 against KB and HL60 whatever the number of Au(III) 
moieties introduced. These phosphorus dendrimers displayed highly anti-proliferative activities 
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against KB and HL-60 in comparison with both 1G3-Cu48 and 1G3-[NN30-PEG18,], 1G3-[NN40-PEG8], 
and 1G3-[NN44-PEG4]. No cumulative effect of Cu(II) was observed in the presence of Au(III). Equal to 
or above 10 [AuCl2]
+ introduced on the surface of 1G3 no further increase was noticed on the anti-
proliferative activities against KB and HL-60 cell lines, as well as the association of Cu(II) to Au(III) had 
no additive effect, suggesting that a threshold might exist in the antiproliferative activity of Au 
complexed dendrimers. Of interest is the fact that the increase of the number of PEG on the surface 
of the dendrimer provokes partially the decrease of the antitumoral potency of the dendrimer. This 
might be tentatively explained by a hindered access of the terminal Au units to the tumor cells due to 
the presence of 18 PEG units on the surface of dendrimer. Such effect is more pronounced in the 
case of KB cell lines: for example, 1G3-[Au15-NN15-PEG18] [AuCl4]15 displayed IC50’ of ~80-100 nM 
versus 10-20 nM for 1G3-[Au20-NN20-PEG8] [AuCl4]20. However such a phenomenon is not so marked 
when the number of PEG units is decreased from 8 to 4 (see Table 2) 
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Figure 3: 2D chemical structure of 1G3-[NN44-PEG4], 1G3-[NN40-PEG8], 1G3-[NN30-PEG18], 1G3-[Au15-
NN15-PEG18] [AuCl4]15, 1G3-[Au40-PEG8] [AuCl4]40, 1G3-[Au20-NN20-PEG8] [AuCl4]20, 1G3-[Au22-NN22-
PEG4] [AuCl4]22, 1G3-[Au20-Cu20-PEG8] [AuCl4]20, 1G3-[Au10-Cu20-NN10-PEG8] [AuCl4]10 
 
IC50 (nM) KB HL60 EPC 
1G3-[NN44-PEG4] >1000 >1000 >1000 
1G3-[NN40-PEG8] >1000 >1000 >1000 
1G3-[NN30-PEG18] >1000 >1000 >1000 
1G3-[Au15-NN15-PEG18] [AuCl4]15 87±7 >1000 >1000 
1G3-[Au20-NN20-PEG8] [AuCl4]20 15±5 4.5±0.5 >1000 
1G3-[Au22-NN22-PEG4] [AuCl4]22 6.7±4.6 3±0.5 >1000 
1G3-[Au20-Cu20-PEG8] [AuCl4]20 8.5±0.7 2.5±0.7 >1000 
1G3-[Au10-Cu20-NN10-PEG8] [AuCl4]10  10±3 4±3 >1000 
1G3-[Au40-PEG 8 ] [AuCl4 ]40 5.5±0.5 1.7±0.5 >1000 
 
Table 2. Antiproliferative activities of 1G3-[NN44-PEG4], 1G3-[NN40-PEG8], 1G3-[NN30-PEG18], 1G3-
[Au15-NN15-PEG18] [AuCl4]15, 1G3-[Au40-PEG8] [AuCl4]40, 1G3-[Au20-NN20-PEG8] [AuCl4]20, 1G3-[Au22-
NN22-PEG4] [AuCl4]22, 1G3-[Au20-Cu20-PEG8] [AuCl4]20, 1G3-[Au10-Cu20NN10-PEG8] [AuCl4]10 
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Figure 4. Antiproliferative activities (KB and HL60) of 1G3-Cu48, 1G3-[Au10-Cu20-NN10-PEG8] [AuCl4]10, 
1G3-[Au15-NN15-PEG18] [AuCl4]15, 1G3-[Au20-NN20-PEG8] [AuCl4]20,1G3-[Au20-Cu20-PEG8] [AuCl4]20, 
1G3-[Au22-NN22-PEG4] [AuCl4]22, 1G3-[Au40-PEG8] [AuCl4]40 and 1G3-[Au48] [AuCl4]48 
 
 
Figure 5. Antiproliferative activities related to the number of AuCl2
+ moieties on the surface of 1G3 
phosphorus dendrimers. 
The antiproliferative activity of 1G3-Cu48 was the result of the activation of the apoptotic cascade 
leading to DNA fragmentation. Therefore, we evaluate the capacity of 1G3-[Au48] [AuCl4]48 to 
promote DNA fragmentation, estimated by TUNEL analysis. Basically, nick-end DNA strands were 
tagged by BrdU and a FITC-labelled anti BrdU antibody. Cells were separated by flow cytometry 
technique (FACS: fluorescence-activated cell sorting) and the green fluorescence intensity was 
monitored in individual cells separated also by flow cytometry. Consequently, the green fluorescence 
intensity is the reflect of the DNA fragmentation in each cell. The amount of total cellular DNA in the 
same cells was detected with propidium iodide giving a red fluorescence (supplemental data S1). The 
number of HL-60 cells with fragmented DNA raised from 2±1% in cells treated with DMSO alone, to 
12±2% in cells treated for 24h with 20 nM AuCl3 + DMSO and from 15±8 to 55±20% with increasing 
concentration of 1G3-[Au48] [AuCl4]48 ranged 5 to 20 nM. In the same conditions 1 µM 1G3 elicited a 
modest 10±10% augmentation of DNA fragmentation in HL-60 cells. This clearly suggested that 1G3-
[Au48] [AuCl4]48 like 1G3-Cu was capable to activate the apoptotic process in dividing cells. 
Through the above example it is clear that the antiproliferative activities against KB and HL60 cell 
lines necessitate only a small amount of Au complexed on the surface of the phosphorus dendrimer 
of generation 3. 
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Next, we decided to test 1G3-[Au48] [AuCl4]48, 1G3-[Au20-Cu20-PEG8] [AuCl4]20 (dual Au-Cu phosphorus 
dendrimer) and 1G3-[Au40-PEG8] [AuCl4]40 against MCF7 human breast adenocarcinoma cell line, PC3 
prostatic small cell carcinoma and MRC5 non-tumoral human lung cells (Table 3). 
 
IC50 (nM) MCF7 PC3 MRC5 
1G3-[Au48] [AuCl4]48 6±2 1.5±0.7 6±2 
1G3-[Au40-PEG8 ] [AuCl4 ]40 2.5±0.7 0.5±0.1 2.7±0.3 
1G3-[Au20-Cu20-PEG8] [AuCl4]20 60±15 13±2 32±8 
 
Table 3. Anti-proliferative activities of 1G3-[Au48] [AuCl4]48, 1G3-[Au20-Cu20-PEG8] [AuCl4]20 and 1G3-
[Au40-PEG8] [AuCl4]40 
These three metallo-dendrimers displayed moderate to good anti-proliferative activities against all 
three cell lines. 1G3-[Au48] [AuCl4]48 showed good anti-proliferative activities with IC50s =1.5 to 6nM, 
1G3-[Au40-PEG8] [AuCl4]40 is the most potent dendrimer against the three cell lines (IC50s= 0.5 to 
2.7nM) whereas (1G3-[Au20-Cu20-PEG8] [AuCl4]20 is the less potent one (IC50s= 13 to 60 nM). These 
data fully confirm the potential antitumoral profile of phosphorus dendrimers bearing gold metal, or 
dual gold-copper metals. 
The next step was to check if a modification of the backbone of the dendrimer can modify the 
potency of the dendrimer. For such a purpose a green chromophore having outstanding two photon 
absorption properties was introduced at the level of the dendrimer of generation 1, then the 
construction of the generation 2 from the twelve chromophoric branches was carried on leading to a 
dendrimer bearing 24 terminal P(S)Cl2  Simultaneous addition of 12 equivalents of phenol PEG and 12 
equivalents of the phenol bearing iminopyridino ligands affords the dendrimer of generation 2 which 
was submitted to complexation with Au(III) to give the phosphorus dendrimer 2G2-[Fluo12-Au16-
PEG8][Au Cl4]16 It is interesting to note that the size of this dendrimer is roughly the same to that of 
1G3-[Au20-PEG8] [AuCl4]20 due to the length of the internal chromophoric linkages (Scheme 1). 
Remarkably such a fluorescent dendrimer keeps in a high level the antiproliferative activities against 
KB and HL60: IC50s of 60-70 nM and 40-50 nM against KB and HL60 respectively. The presence of PEG 
units maintains the water solubility, thus allowing us to consider such a dendrimer as a good 
candidate for further in vitro and in vivo imaging studies in tumor cell lines.  
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Scheme 1. Synthesis of the dendrimer bearing 12 internal fluorophore units 2G2-[Fluo12-Au16] [PEG]8 
[AuCl4 ]16 
 
Antimicrobial activities  
Some of these metallophosphorus dendrimers were evaluated for an antibacterial and antifungal 
activity against the strains: Gram positive bacterium (Staphylococcus aureus ATCC 6538), Gram 
negative bacteria (Escherichia coli ATCC 8739, Pseudomonas aeruginosa ATCC 27853) and yeasts 
(Candida albicans ATCC 10231), but also against drug-resistant clinical strains: Gram positive bacteria 
(Staphylococcus aureus ZMF KSK, Enterococcus faecalis ZMF BD 156) and yeasts Candida glabrata 
ZMF SZP 4. The MIC (minimal inhibitory concentration) values were the lowest concentrations of the 
compound with no measurable optical density increase. The MBC (minimal bactericidal 
concentration) values were the lowest concentrations of the compound that killed all cells and as a 
result there was no growth of a subculture on the surface of a Petri dish. The obtained results 
(Figures 6, 7 and Table 4) indicate that all dendrimers have a wide spectrum of 
bacteriostatic/fungistatic activity. Also in some cases they have bactericidal and fungicidal activity 
(MIC=MBC) in a concentration range of 3.5-500 mg/L. 1G3-[Au48] [AuCl4]48 dendrimer has the biggest 
number of monomers 1 in the structure, resulting in the biggest number of Au atoms (96) and the 
highest antimicrobial activity. In turn the monomer 1 having two Au atoms is the second one in 
antimicrobial activity ranking. There are many reports on Au(I) and Au(III) complexes studied for 
antimicrobial activity against a wide variety of microorganisms.30,31,32,33 Among studies on 
antimicrobial potential of different nanoparticles, the gold nanoparticles represent a broad group of 
compounds.34,35,36,37 Mechanism of antibacterial activity of AuNP, proposed by Cui et al. suggests that 
the death of bacterial cells is due to attachment of these nanoparticles to the bacterial membrane 
followed by membrane potential modification and ATP level decrease and secondly inhibition of 
tRNA binding to the ribosome.38 The most sensitive bacterium towards all tested compounds is Gram 
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negative E. coli. The difference in peptidoglycan layer’s thickness in Gram-positive and Gram-
negative bacteria membrane (50% higher in Gram positive) may explain the fact, that in many studies 
larger doses of nanoparticles are required for Gram-positive bacteria. However, in case of 
metallophosphorus dendrimers high sensitivity was also observed for Gram positive S. aureus (type 
strains). Umadevi et al.39 showed that AgNPs were most effective against E. coli, which membrane 
exhibits a high permeability, leaving the bacterial cells incapable of properly regulating transport 
through the plasma membrane and causing cell death. It was shown that metal particles formed 
irregular-shaped pits in the outer membrane of E. coli and changed membrane permeability.40,41,42 
Comparing the sensitivity of bacteria, the lower toxicity of tested compounds toward clinical 
resistant strains was observed (S. aureus ATCC 6538 versus S. aureus ZMF KSK). The mechanisms of 
bacterial resistance may be intrinsic to the species or acquired through mutation of intrinsic genes or 
horizontal exchange of genetic material encoding resistance determinants. P. aeruginosa and E. 
faecalis are the examples of highly intrinsic resistant bacteria. Low susceptibility of P. aeruginosa to 
antibiotics is mainly the consequence of the loss of porin43 and the presence of several genes 
encoding multidrug resistance (MDR) efflux pumps in its genome.44 Hollenback and Rice45 reviewed 
the mechanisms underlying antibiotic resistance in enterococci to virtually all clinically useful 
antibiotics (aminoglycosides, β-lactams, cephalosporins, lincosamides, glycopeptides and 
streptogramins). We have noticed that the lowest concentration 62.5 mg/L of 1G3-[Au48][AuCl4]48 
killed all P. aeruginosa cells while the monomer 1 in a concentration of 125 mg/L has bacteriostatic 
activity against the same strain. 
E. faecalis ZMF BD 156 sensitivity toward monomer 1 is the same as P. aeruginosa sensitivity (MIC 
125 mg/L, MBC 500 mg/L) and a little bit lower towards 1G3-[Au48][AuCl4]48 (bactericidal activity at 
125 mg/L). Those results are very promising. However, some compounds (for example trimethoprim-
sulfamethoxazole) despite in vitro enterococcal susceptibility are ineffective in treating serious 
enterococcus infections.46 Among the studied molecules, 1G3-[Au10-Cu20-NN10-PEG8] [AuCl4 ]10 (with 
copper and gold in the structure) exhibited the greatest antifungal activity against Candida albicans 
ATCC 10231 and Candida glabrata ZMF SZP4 (MIC=MBC 62,5 mg/L). The main components of 
Candida membrane are β−1,3-glucan, β−1,6-glucan, chitin and two classes of proteins (they may 
constitute even 40%): GPI - linked to β−1,6-glucan through a glycophosphatidylinositol and Pir 
(proteins with internal repeats) - linked directly to the β-1,3-glucan.47 A large number of studies have 
used copper in various forms, concentration, and environment to test the antimicrobial properties, 
which are mostly based on “contact killing”. Metallic copper can alter the tertiary structure of 
proteins, which leads to damage of the bacterial envelope and might constitute a primary killing 
mechanism.48,49 
Copper is also present in the structure of 1G3 [Cu44-PEG4], where the fungicidal effect is observed in 
a concentration of 250 mg/L. So, we can assume the synergistic effect between Au and Cu in case of 
1G3-[Au10-Cu20-NN10-PEG8] [AuCl4]10. 
1G3-[Au10-Cu20-NN10-PEG8] [AuCl4]10 presented also bacteriostatic activity to E. coli. Domek et al.
50 
claimed that copper considerably influences metabolism of E. coli. According to their results cooper 
impairs respiratory activity causing a decrease of oxygen uptake and in consequence the rate of 
utilisation of glucose and succinate which are the main substrates of their aerobic metabolism 
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Figure 6. The MIC (minimal inhibitory concentration) values of best compounds against bacteria and 
yeasts. 
 
Figure 7. The MBC (minimal bactericidal concentration) values of best compounds against bacteria 
and yeasts. 500* means >500. 
 
 
Table 3. The MIC (minimal inhibitory concentration) and MBC (minimal bactericidal concentration) 
values of tested compounds against bacteria and yeasts.  
 Monomer 1 1G3-[Au48] 1G3-[Au20- 1G3 [Cu44- 1G3-[Au10-Cu20-
Page 14 of 30
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
15 
 
 [AuCl4]48 
 
NN20-PEG8] 
[AuCl4 ]20 
PEG4] NN10-PEG8] 
[AuCl4 ]10 
 MIC 
mg/L 
MBC 
mg/L 
MIC 
mg/L 
MBC 
mg/L 
MIC 
mg/L 
MBC 
mg/L 
MIC 
mg/L 
MBC 
mg/L 
MIC 
mg/L 
MBC 
mg/L 
Type strains           
S. aureus  
ATCC 6538 
62.5 62.5 3.9 15.6 250 250 250 >500 500 500 
E. coli  
ATCC 8739 
7.81 15.6 7.8 15.6 62.5 62.5 500 500 62.5 500 
P. aeruginosa 
ATCC 27853 
125 500 62.5 62.5 250 250 >500 >500 250 >500 
C. albicans  
ATCC 10231 
125 250 250 >500 >500 >500 250 250 62.5 62.5 
Clinical 
strains 
          
S. aureus   
ZMF KSK  
125 >500 62.5 125 250 500 >500 >500 250 500 
E. faecalis  
ZMF BD 156 
125 500 125 125 500 500 250 >500 250 >500 
C. glabrata  
ZMF SZP 4 
125 250 250 >500 125 >500 250 250 
 
62.5 62.5 
 
Conclusion 
In conclusion, new metallodendrimers have been prepared by the replacement of Cu(II) on the 
phosphorus dendrimer surface by Au(III). The complexation of the dendrimer with Au(III) strongly 
increased (~30-fold) the anti-proliferative activities against both KB and HL-60. 1G3-[Au48] [AuCl4]48 
showed IC50’s in the low nanomolar range (IC50’s of 7.5 nM and 3 3 nM against KB and HL60, 
respectively). It can be noticed also that 1G3-[Au48] [AuCl4]48 displayed low activity on the quiescent 
cell line EPC versus its potent antiproliferative activity against actively dividing cells. This is in line 
with the activation of DNA fragmentation reported herein. Interestingly, equal to or above 10 Au(III) 
introduced on the surface of 1G3 no further increase of potency was noticed on the anti-proliferative 
activities against KB and HL-60 cell lines, as well as the association of Cu(II) to Au(III) had no additive 
effect, suggesting that a threshold might exist in the antiproliferative activity of Au complexed 
dendrimers.  
Taken together, these results strongly demonstrate that 1G3-[Au48] [AuCl4]48 and 1G3-[Aux]-[NN]-
[PEG)] [AuCl4]x in which x is equal to or above 10 displayed similar impressive anti-proliferative 
activities (nanomolar range) and represent new nanodevices in the oncology domain. The oncology 
field remains one of the most challenging therapeutic area despite the considerable progress made 
with the new molecularly targeted therapies. For many patients the therapeutic options are still 
limited, and the process of bringing a new drug to patients is still frustratingly slow with high failure 
rates. Oncology is one of the poorest record for IND (Investigational NEW Drugs) in clinical 
development (~5%), low and decreasing response rates in Phase I oncology trials (~2-3%), and 
treatment-related to death rate (<1%). Consequently, the search and development of new chemical 
entities continued to be a reality to kill all tumor cells including resistants within a specific tumor 
heterogeneity (microenvironment issue) and low translational success. The use of these metallo 
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phosphorus dendrimers represents therefore a way to make additional advances in such a topic and 
illustrated the great potentiality of phosphorus dendrimers.51,52,53,54 
On the other hand all tested metallophosphorus dendrimers have antimicrobial and antifungal 
activity against studied microorganisms in a concentration range of 3.5-500 mg/L. 1G3-
[Au48][AuCl4]48 has the highest antimicrobial activity, whereas 1G3-[Au10-Cu20-NN10-PEG8] [AuCl4]10 
the highest antifungal activity. The most sensitive bacterium towards all tested compounds is Gram 
negative E. coli. In marked contrast with the results reported above on the oncology domain where 
no synergistic effect between Au and Cu is observed, a marked synergistic effect was found for their 
antifungal activity when these two metals are both present in the same phosphorus dendrimer 
structures. These results illustrate the versatile and dual behavior of phosphorus dendrimers and 
their complexes and open new possibilities to use them in nanomedicine 
 
Experimental part 
The syntheses were carried out using standard high vacuum and dry-argon techniques (see 
supplementary material). All chemicals were purchased from Acros, Aldrich, Fluka, and used without 
further purification. The solvents were freshly dried and distilled according to standard procedures 
prior to use. 
Crystallographic data for compound 1 
Data were collected at low temperature (193(2) K) on a Bruker Kappa Apex II diffractometer 
equipped with a 30 W air-cooled microfocus, using MoKα radiation (λ = 0.71073 Å), and an Oxford 
Cryosystems Cryostream cooler device. Phi- and omega- scans were used for data collection. The 
structure was solved by direct methods with SHELXS-97. All non-hydrogen atoms were refined 
anisotropically by means of least-squares procedures on F² with SHELXL-9755. The hydrogen atoms 
were refined isotropically at calculated positions using a riding model. Crystal structure(s) have been 
deposited at the Cambridge Crystallographic Data Centre. The data have been assigned to the 
following deposition numbers.CCDC 155286: Summary of Data CCDC 1552863:  
Compound Name: 1 
Formula: C15 H16 Au1 Cl2 N2 O1 
1+ Au1 Cl4 
1-Unit Cell Parameters: a 7.9555(4) b 8.3100(4) c 16.8431(8) P-
1 
Cell culture  
The human cell line KB (nasopharyngeal epidermis carcinoma) was originated from the NCI, MRC5-
SV2 (human lung fibroblast) cells were purchased from ECACC (Salisbury, UK) and HL60 
(promyeocytic leukaemia) and EPC (carp skin epithelium) cells from ATCC. KB and MRC5 cells were 
grown in D-MEM medium supplemented with 10% foetal calf serum, in the presence of penicillin, 
streptomycin and fungizone in 75 cm² flask under 5% CO2, whereas all other cell lines were grown in 
complete RPMI medium.  
Cell proliferation assay. Cells were plated in 96-well tissue culture with dendrimers dissolved in 
DMSO (1% final volume). After 72 h exposure, MTS reagent (Promega) was added and incubated for 
3 h at 37 °C: the absorbance was monitored at 490 nm, and results are expressed as the inhibition of 
cell proliferation calculated as the ratio [(1 − (OD490 treated/OD490 control)) × 100]. For IC50 
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determinations (50% inhibition of cell proliferation) experiments were performed in duplicate. All IC50 
values were calculated on a molar dendrimer basis to accurately compared dendrimers with the same numbers 
of terminal groups (n = 48) and variable number of metal atoms and PEG groups 
TUNEL (terminal deoxynucleotidyl transferase nick-end labelling) assay for DNA strand break. 15,000 
cells were seeded in 100 µl medium in 96 w microplate and treated for 24h with 1G3 and 1G3-Au 
dissolved in DMSO. Cells were fixed in paraformaldehyde, permeabilized with 70% ethanol and 
incubated with BrdU and TdT at 37°C for 40 min. Cells were analyzed by FACS (fluorescence-activated 
cell sorting) after 1h incubation with anti BrdU-FITC antibody and PI. Cell populations were quantified 
using Modfit LT (Verity Software House). 
Antimicrobial activity 
Methods used for in vitro microbial susceptibility tests were employed in compliance with M7-A7 and 
M27A3 instructions according to Clinical and Laboratory Standards Institute (CLSI).56,57 Antimicrobial 
activity was assayed against Gram-positive bacteria Staphylococcus aureus ATCC 6538P, Gram-
negative bacteria Escherichia coli ATCC 8739, Pseudomonas aeruginosa ATCC 27853, and yeasts 
Candida albicans ATCC 10231 - strains commonly used for such tests. Additionally, antimicrobial 
activity was tested against multiresistant Staphylococcus aureus ZMF KSK strain, which was resistant 
to all beta-lactams (MRSA –Methicillin Resistant Staphylococcus aureus) and streptomycin, but its 
MIC value for AgNO3 was 15.6 mg/L and MBC>500 mg/L. Another two strains Enterobacter faecalis 
ZMF BD156 (Gram-positive bacteria) and Candida glabrata ZMF40 (yeasts) were isolated from clinical 
specimens from humans. 
Analysed compounds were suspended in dimethylsulfoxide (DMSO – analytical grade) and then in 
Mueller Hinton Broth (BioMaxime) for bacteria and in RPMI-1640 Medium (Sigma) for yeasts. 
Consecutive two-fold dilutions were prepared in a microtiter tray (concentrations from 500 to 3.9 
mg/L).  
Tested strains were inoculated into each well of microtiter plate at concentration of 106 CFU per 1 
mL. After 24-hour incubation at 37°C for bacteria and 48 hours at 25oC for yeasts an increase of 
turbidity was measured at 630 nm by means of microplate reader (MR 680 Bio-Rad). The MIC 
(minimal inhibitory concentration) values was the lowest concentration of the investigated 
compounds with no measurable optical density increase. The MBC (minimal bactericidal 
concentration) values was the lowest concentrations of the compound that killed all cells and as a 
result there was no growth of a subculture on the surface of Petri dish containing proper for each 
organism agar medium and after 24 or 48-hours incubation at an appropriate temperature. 
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Figure 1. Chemical structure of 1G3, 1G3-Cu48 and 1G3-[Au48] [AuCl4]48 dendrimers X = nothing for 
1G3; X = CuCl2 for 1G3-Cu48; X = [AuCl2] [AuCl4] for 1G3-[Au48] [AuCl4]48  
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Figure 2. Chemical structure and X-ray structure of the Au(III)-monomer complex 1  
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Figure 3. 2D chemical structure of 1G3-[NN44-PEG4], 1G3-[NN40-PEG8], 1G3-[NN30-PEG18], 1G3-
[Au15-NN15-PEG18] [AuCl4]15, 1G3-[Au40-PEG8] [AuCl4]40, 1G3-[Au20-NN20-PEG8] [AuCl4]20, 1G3-
[Au22-NN22-PEG4] [AuCl4]22, 1G3-[Au20-Cu20-PEG8] [AuCl4]20, 1G3-[Au10-Cu20-NN10-PEG8] 
[AuCl4]10  
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Figure 4. Antiproliferative activities (KB and HL60) of 1G3-Cu48, 1G3-[Au10-Cu20-NN10-PEG8] [AuCl4]10, 
1G3-[Au15-NN15-PEG18] [AuCl4]15, 1G3-[Au20-NN20-PEG8] [AuCl4]20,1G3-[Au20-Cu20-PEG8] 
[AuCl4]20, 1G3-[Au22-NN22-PEG4] [AuCl4]22, 1G3-[Au40-PEG8] [AuCl4]40 and 1G3-[Au48] [AuCl4]48  
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Figure 5. Antiproliferative activities related to the number of AuCl2
+ moieties on the surface of 1G3 
phosphorus dendrimers  
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Figure 6. The MIC (minimal inhibitory concentration) values of best compounds against bacteria and yeasts. 
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Figure 7. The MBC (minimal bactericidal concentration) values of best compounds against bacteria and 
yeasts. 500* means >500.  
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Scheme 1. Synthesis of the dendrimer bearing 12 internal fluorophore units 2G2-[Fluo12-Au16] [PEG]8 
[AuCl4 ]16  
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